Answers are grounded in this paper and cite their sources.
To investigate the costs and profile of patients who have filed a lawsuit against the Ministry of Health for the treatment of spinal muscular atrophy (SMA) with the onasemnogene abeparvovec (Zolgensma®).
No takes yet. Share an insight, caveat, or question.
Kretzschmar et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: